Aarti Drugs Limited

AARTIDRUGS

INE767A01016

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:47 2024-04-25 am EDT			5-day change	1st Jan Change
500.4 ^INR	-0.18%		+1.44%	+2.32%

Mar. 29	Aarti Drugs Limited Announces Executive Cessation	CI
Jan. 31	Aarti Drugs Begins Manufacturing Dermatology Products in Tarapur, India Facility	MT

Tranche Update on Aarti Drugs Limited's Equity Buyback Plan announced on October 17, 2016.

December 28, 2016 at 02:24 am EST

From December 2, 2016 to December 16, 2016, the company has repurchased 360,000 shares, representing 1.49% for INR 270 million. With this, the company has completed the repurchase of 360,000 shares, representing 1.49% for INR 270 million under the buyback announced on October 17, 2016.

Latest news about Aarti Drugs Limited

Aarti Drugs Limited Announces Executive Cessation	Mar. 29	CI
Aarti Drugs Begins Manufacturing Dermatology Products in Tarapur, India Facility	Jan. 30	MT
Aarti Drugs Limited Initiates Commercial Production of Dermatology Product At New Facility in Tarapur, Maharashtra	Jan. 30	CI
Transcript : Aarti Drugs Limited, Q3 2024 Earnings Call, Jan 25, 2024	Jan. 25
Aarti Drugs Limited Announces Interim Dividend for the Financial Year 2023- 24	Jan. 24	CI
Aarti Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 24	CI
Transcript : Aarti Drugs Limited, Q2 2024 Earnings Call, Oct 20, 2023	23-10-20
Aarti Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-19	CI
Tranche Update on Aarti Drugs Limited's Equity Buyback Plan announced on July 21, 2023.	23-08-28	CI
Aarti Drugs Limited's Equity Buyback announced on July 21, 2023, has closed with 665,000 shares, representing 0.72% for INR 598.5 million.	23-08-16	CI
Aarti Drugs Clocks Gains in Fiscal Q1 Consolidated Profit	23-07-24	MT
Transcript : Aarti Drugs Limited, Q1 2024 Earnings Call, Jul 24, 2023	23-07-24
Aarti Drugs Limited announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million.	23-07-21	CI
Aarti Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-21	CI
Aarti Drugs Limited authorizes a Buyback Plan.	23-07-20	CI
Aarti Drugs Limited's Board intends to launch an Equity Buyback on July 21, 2023.	23-07-14	CI
Aarti Drugs Limited's Board intends to launch an Equity Buyback on July 21, 2023.	23-07-14	CI
Transcript : Aarti Drugs Limited, Q4 2023 Earnings Call, May 02, 2023	23-05-02
Aarti Drugs' Consolidated Profit Climbs in Fiscal Q4	23-05-01	MT
Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-04-29	CI
Transcript : Aarti Drugs Limited, Q3 2023 Earnings Call, Jan 30, 2023	23-01-30
Aarti Drugs' Consolidated Net Profit Declines in Fiscal Q3	23-01-30	MT
Aarti Drugs Limited Declares Interim Dividend for the Financial Year 2022-23	23-01-27	CI
Aarti Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-01-27	CI
Aarti Drugs' Consolidated Profit Falls in Fiscal Q2	22-10-21	MT

Chart Aarti Drugs Limited

Duration

Period

More charts

Company Profile

Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Aarti Drugs Limited

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

500.4 INR

Average target price

562 INR

Spread / Average Target

+12.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AARTI DRUGS LIMITED	+2.32%	553M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals

Aarti Drugs Limited

Equities

AARTIDRUGS

INE767A01016

Pharmaceuticals

Tranche Update on Aarti Drugs Limited's Equity Buyback Plan announced on October 17, 2016.

Latest news about Aarti Drugs Limited

Chart Aarti Drugs Limited

Company Profile

Income Statement Evolution

Ratings for Aarti Drugs Limited

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals